logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

ENYO Pharma raised €32 million in its Series C financing with a new €6 million investment from Vesalius Biocapital IV to support clinical studies and research in severe kidney diseases.

Jun 12, 2025•6 months ago

Amount Raised

€32 Million

Round Type

series c

LyonBiotechnology

Investors

Vesalius Biocapital Iv

Description

ENYO Pharma announced the completion of its Series C financing round with a total raise of €32 million, including a new investment of €6 million from Vesalius Biocapital IV. The funds will support two additional clinical studies and expand preclinical research efforts. With this funding, ENYO aims to further its research in severe kidney diseases, particularly in Alport syndrome. The company anticipates topline results from its ALPESTRIA-1 Phase 2 trial by Q4 2025.

Company Information

Company

ENYO Pharma

Location

Lyon, Auvergne Rhône Alpes, France

About

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH).

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech